Literature DB >> 27260403

Altered secondary structure of Dynorphin A associates with loss of opioid signalling and NMDA-mediated excitotoxicity in SCA23.

Cleo J L M Smeets1, Justyna Zmorzyńska1, Manuel N Melo2, Anita Stargardt3, Colette Dooley4, Georgy Bakalkin5, Jay McLaughlin6, Richard J Sinke1, Siewert-Jan Marrink2, Eric Reits3, Dineke S Verbeek1.   

Abstract

Spinocerebellar ataxia type 23 (SCA23) is caused by missense mutations in prodynorphin, encoding the precursor protein for the opioid neuropeptides α-neoendorphin, Dynorphin (Dyn) A and Dyn B, leading to neurotoxic elevated mutant Dyn A levels. Dyn A acts on opioid receptors to reduce pain in the spinal cord, but its cerebellar function remains largely unknown. Increased concentration of or prolonged exposure to Dyn A is neurotoxic and these deleterious effects are very likely caused by an N-methyl-d-aspartate-mediated non-opioid mechanism as Dyn A peptides were shown to bind NMDA receptors and potentiate their glutamate-evoked currents. In the present study, we investigated the cellular mechanisms underlying SCA23-mutant Dyn A neurotoxicity. We show that SCA23 mutations in the Dyn A-coding region disrupted peptide secondary structure leading to a loss of the N-terminal α-helix associated with decreased κ-opioid receptor affinity. Additionally, the altered secondary structure led to increased peptide stability of R6W and R9C Dyn A, as these peptides showed marked degradation resistance, which coincided with decreased peptide solubility. Notably, L5S Dyn A displayed increased degradation and no aggregation. R6W and wt Dyn A peptides were most toxic to primary cerebellar neurons. For R6W Dyn A, this is likely because of a switch from opioid to NMDA- receptor signalling, while for wt Dyn A, this switch was not observed. We propose that the pathology of SCA23 results from converging mechanisms of loss of opioid-mediated neuroprotection and NMDA-mediated excitotoxicity.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27260403     DOI: 10.1093/hmg/ddw130

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

Review 1.  Dynorphins in Development and Disease: Implications for Cardiovascular Disease.

Authors:  Cody Cissom; Jason J Paris; Zia Shariat-Madar
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

2.  Dysregulated kappa-opioid receptors in the medial prefrontal cortex contribute to working memory deficits in alcohol dependence.

Authors:  Gengze Wei; Sunil Sirohi; Brendan M Walker
Journal:  Addict Biol       Date:  2022-03       Impact factor: 4.093

3.  Dynorphin A induces membrane permeabilization by formation of proteolipidic pores. Insights from electrophysiology and computational simulations.

Authors:  D Aurora Perini; Marcel Aguilella-Arzo; Antonio Alcaraz; Alex Perálvarez-Marín; María Queralt-Martín
Journal:  Comput Struct Biotechnol J       Date:  2021-12-16       Impact factor: 7.271

4.  Cerebellar developmental deficits underlie neurodegenerative disorder spinocerebellar ataxia type 23.

Authors:  Cleo J L M Smeets; Kai Yu Ma; Simon E Fisher; Dineke S Verbeek
Journal:  Brain Pathol       Date:  2020-11-02       Impact factor: 6.508

5.  Functional Characterization of Spinocerebellar Ataxia Associated Dynorphin A Mutant Peptides.

Authors:  Andreas Lieb; Germana Thaler; Barbara Fogli; Olga Trovato; Mitja Amon Posch; Teresa Kaserer; Luca Zangrandi
Journal:  Biomedicines       Date:  2021-12-11

Review 6.  Spinocerebellar ataxia type 23 (SCA23): a review.

Authors:  Fan Wu; Xu Wang; Xiaohan Li; Huidi Teng; Tao Tian; Jing Bai
Journal:  J Neurol       Date:  2020-11-11       Impact factor: 6.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.